Service Incident: New DOI registrations are working again. Re-registration of failed DOI registrations (~500) are still affected by the service incident at DataCite (our DOI registration agency).
Published January 27, 2019 | Version v1
Journal article Open

Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury

  • 1. Assist. Prof. M.D.; Abant Izzet Baysal University School of Medicine, Department of Orthopaedic and Traumatology, 14030, Bolu, Turkey

Description

Metformin is one of the safest drugs used to control blood sugar in diabetes. This drug is being investigated by orthopedists as well as by neurosurgeons as it may increase the locomotor recovery after spinal cord injury (SCI). In the present study, the aim was to evaluate a promising pharmacological agent, metformin, which is known to be used in SCI treatment by acting over the mammalian target of rapamycin (mTOR) and some other signaling pathway. Relevant clinical trials were included in the study following electronic database scan.  Preclinical and cellular studies have demonstrated that metformin may have antitumoral properties, regulate inflammation, and therefore play a role in the tumor microenvironment, or that it has a therapeutic effect in SCI by acting over mTOR pathway. However, Level of I clinical trials should be performed to determine the effectiveness of metformin in SCI, a serious pathology.

Files

Files (161.1 kB)

Name Size Download all
md5:a5d87a0c1cebc1ef2e598c5a301db164
161.1 kB Download